OBJECTIVE: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. METHODS: Medication and demographic data from the Alzheimer's Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimer's disease (AD), and effects of demographic variables were assessed using logistic regression. RESULTS: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. CONCLUSIONS: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.
OBJECTIVE: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. METHODS: Medication and demographic data from the Alzheimer's Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimer's disease (AD), and effects of demographic variables were assessed using logistic regression. RESULTS: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. CONCLUSIONS: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.
Authors: D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson Journal: Neurology Date: 1998-12 Impact factor: 9.910
Authors: David S Knopman; Joel H Kramer; Bradley F Boeve; Richard J Caselli; Neill R Graff-Radford; Mario F Mendez; Bruce L Miller; Nathaniel Mercaldo Journal: Brain Date: 2008-10-01 Impact factor: 13.501
Authors: W Liu; B L Miller; J H Kramer; K Rankin; C Wyss-Coray; R Gearhart; L Phengrasamy; M Weiner; H J Rosen Journal: Neurology Date: 2004-03-09 Impact factor: 9.910
Authors: Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel Journal: JAMA Date: 2004-01-21 Impact factor: 56.272
Authors: Adam L Boxer; Anne M Lipton; Kyle Womack; Jennifer Merrilees; John Neuhaus; Danijela Pavlic; Anisha Gandhi; Dana Red; Kristen Martin-Cook; Doris Svetlik; Bruce L Miller Journal: Alzheimer Dis Assoc Disord Date: 2009 Jul-Sep Impact factor: 2.703
Authors: Andrea Slachevsky; Carlos Muñoz-Neira; Javier Nuñez-Huasaf; Theodore A Stern; Carl R Blesius; Alireza Atri Journal: Prim Care Companion CNS Disord Date: 2011
Authors: Maria Carmela Tartaglia; Bei Hu; Kala Mehta; John Neuhaus; Kristine Yaffe; Bruce L Miller; Adam Boxer Journal: Alzheimer Dis Assoc Disord Date: 2014 Apr-Jun Impact factor: 2.703
Authors: Adam L Boxer; David S Knopman; Daniel I Kaufer; Murray Grossman; Chiadi Onyike; Neill Graf-Radford; Mario Mendez; Diana Kerwin; Alan Lerner; Chuang-Kuo Wu; Mary Koestler; Jill Shapira; Kathryn Sullivan; Kristen Klepac; Kristine Lipowski; Jerin Ullah; Scott Fields; Joel H Kramer; Jennifer Merrilees; John Neuhaus; M Marsel Mesulam; Bruce L Miller Journal: Lancet Neurol Date: 2013-01-02 Impact factor: 44.182
Authors: Pascual Sánchez-Juan; Pia M Ghosh; Jayne Hagen; Benno Gesierich; Maya Henry; Lea T Grinberg; James P O'Neil; Mustafa Janabi; Eric J Huang; John Q Trojanowski; Harry V Vinters; Marilu Gorno-Tempini; William W Seeley; Adam L Boxer; Howard J Rosen; Joel H Kramer; Bruce L Miller; William J Jagust; Gil D Rabinovici Journal: Neurology Date: 2013-12-18 Impact factor: 9.910
Authors: Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings Journal: Alzheimers Dement Date: 2012-10-10 Impact factor: 21.566